Back to News
Market Impact: 0.4
Lucid Shares Jump 40% Overnight On EsoGuard Medicare Payments, $15 Mln Financing
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsPrivate Markets & Venture
Lucid Diagnostics shares rose about 40% in overnight trading after the PAVmed subsidiary said it had begun receiving Medicare payments for its EsoGuard Esophageal DNA Test. The company also closed a $15 million private placement.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
LUCD0.75
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas